Calamos Advisors
JAZZ icon

Calamos Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Calamos Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$309K Buy
+1,637
New +$286K ﹤0.01% 990
2023
Q2 		– Sell
-43,770
Closed -$6.4M – 1034
2023
Q1 		$6.4M Sell
43,770
-546
-1% -$80.8K 0.03% 563
2022
Q4 		$7.06M Buy
44,316
+179
+0.4% +$26.2K 0.03% 572
2022
Q3 		$5.88M Buy
44,137
+127
+0.3% +$19.3K 0.03% 636
2022
Q2 		$6.87M Sell
44,010
-925
-2% -$142K 0.03% 612
2022
Q1 		$7M Buy
+44,935
New +$6.52M 0.03% 617
2021
Q3 		– Sell
-16,940
Closed -$3.01M – 1014
2021
Q2 		$3.01M Buy
+16,940
New +$2.93M 0.01% 658
2017
Q2 		– Sell
-68,409
Closed -$9.93M – 628
2017
Q1 		$9.93M Sell
68,409
-139,523
-67% -$18.2M 0.08% 286
2016
Q4 		$22.7M Buy
207,932
+29,939
+17% +$3.33M 0.18% 165
2016
Q3 		$21.6M Buy
177,993
+58,889
+49% +$7.94M 0.15% 184
2016
Q2 		$16.8M Sell
119,104
-69,941
-37% -$10.3M 0.12% 218
2016
Q1 		$24.7M Buy
189,045
+60,489
+47% +$7.53M 0.16% 178
2015
Q4 		$18.1M Buy
128,556
+15,573
+14% +$2.16M 0.11% 201
2015
Q3 		$15M Buy
112,983
+4,455
+4% +$767K 0.1% 216
2015
Q2 		$19.1M Buy
108,528
+104,828
+2,833% +$18.8M 0.12% 200
2015
Q1 		$639K Buy
3,700
+800
+28% +$137K ﹤0.01% 572
2014
Q4 		$475K Sell
2,900
-190,531
-99% -$31.6M ﹤0.01% 607
2014
Q3 		$31.1M Sell
193,431
-217,036
-53% -$33.4M 0.21% 133
2014
Q2 		$60.3M Sell
410,467
-140,023
-25% -$19.4M 0.38% 74
2014
Q1 		$76.3M Sell
550,490
-1,441
-0.3% -$217K 0.49% 49
2013
Q4 		$69.9M Sell
551,931
-631,297
-53% -$65.3M 0.44% 57
2013
Q3 		$109M Sell
1,183,228
-5,374
-0.5% -$434K 0.68% 38
2013
Q2 		$81.7M Buy
+1,188,602
New +$72.7M 0.53% 53

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Calamos Advisors's JAZZ Position: Q1 2026 in Review

Calamos Advisors opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 1,637 shares worth $309K. The stake represents ﹤0.01% of the portfolio and ranks #990 among its holdings. This is a return to the name: Calamos Advisors previously reported a position in JAZZ as recently as Q1 2023.

Calamos Advisors first reported a position in JAZZ in Q2 2013 and has held it in 23 quarters since. The position peaked at $109M in Q3 2013. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Calamos Advisors held 1,637 shares of Jazz Pharmaceuticals worth $309K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Calamos Advisors position in Q1 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q1 2026, its #990 holding.
  • Calamos Advisors first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 23 quarters since.
  • Calamos Advisors's Jazz Pharmaceuticals position peaked at $109M in Q3 2013.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.